Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.

Publication/Presentation Date

1-1-2022

Volume

134

Issue

sup1

First Page

1

Last Page

4

ISSN

1941-9260

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

36691310

Department(s)

Administration and Leadership

Document Type

Article

Share

COinS